IBRX News and Press, ImmunityBio Inc. From 04/23/24

2024-04-23 04:07:51 ET ImmunityBio (NASDAQ: IBRX) stock price resumed its strong rally this week after the company achieved a major milestone. After dropping by over 6% in the regular session on Monday, it rebounded by over 20% in the extended session. FDA approves ANKTIVA This ...

Designated an FDA Breakthrough Therapy, the novel immunotherapy ANKTIVA activates the body’s natural killer (NK) and killer T-cell immune system to attack tumor cells Therapy stimulates memory T cells, leading to long duration of complete response exceeding 47 months and ongoing to dat...

2024-04-17 17:30:13 ET More on ImmunityBio ImmunityBio: Financial And Regulatory Risks Outweigh Anktiva's Promise ImmunityBio: Buy Low Now Vs. Buy High Later Read the full article on Seeking Alpha For further details see: ImmunityBio files automatic mixed...

2024-03-27 10:00:45 ET More on Health Care Select Sector SPDR XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run John...

2024-03-14 08:45:28 ET FN Media Group Presents USA News Group News Commentary Vancouver, BC – March 14, 2024 – USA News Group – Known as one of the most deadly forms of cancer, pancreatic cancer still has the highest mortality rate of all m...

SuRo Capital Corp. (SSSS) is expected to report for quarter end 2023-12-31 Enviva Inc. (EVA) is expected to report $-0.76 for Q4 2023 Jushi Holdings Inc. - Class B (Sub Voting) (JUSHF) is expected to report $-0.04 for Q4 2023 U Power Limited (UCAR) is expected to report for quarter en...

ImmunityBio ( NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced the recent publication of preclinical data in the online issue of Science , First Release indicating that combination therapy with N-803, an IL-15 superagonist, and broadly neutralizing antibo...

2024-03-06 07:40:00 ET Summary A record 39 new analysts joined us in February 2024, bringing fresh perspectives and ideas to the community. Analysts cover a wide range of areas of interest, including value investing, dividend investing, growth stocks, and cryptocurrencies. Som...

Klepierre (KLPEF) is expected to report for Q4 2023 comScore Inc. (SCOR) is expected to report $0.8 for Q4 2023 Universal Stainless & Alloy Products Inc. (USAP) is expected to report for Q4 2023 FAT Brands Inc. (FAT) is expected to report $-1.55 for Q4 2023 Jet.AI Inc. (JTAI) ...

All participants in the Phase 1 pilot study experienced a marked decrease in the burden of infection, and the procedures were found to be safe and well tolerated N-803 is being studied in three other HIV cure-related clinical trials ImmunityBio ( NASDAQ: IBRX ), a clinical-stage...